 investigation of bacterial infections among patients treated with umbilical cord blood derived products marketed as stem cell therapies this outbreak report described how 20 patients in 8 states developed bacterial infections after receiving unapproved products marketed as treatment for conditions including chronic pain and degenerative joint conditions despite warnings from fda these products are increasingly being marketed and can expose patients to serious risks without clear benefit including the possibility of product contamination and risks for serious infections 